- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06389682
Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of 68Ga-NYM005 in Patients
April 24, 2024 updated by: Norroy Bioscience Co., LTD
Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of a Single Dose of Gallium [68Ga]-NYM005 Injection Prepared by Kit for the Preparation of the 68Ga-NYM005 Injection in Patients With Metastatic Clear Cell Renal Carcinoma.
68Ga-NYM005 is a CAIX-targeting small-molecular radiotracer for PET/CT imaging of clear cell renal cell carcinoma
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
12
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Jiangsu
-
Wuxi, Jiangsu, China, 214000
- Recruiting
- Affliated Hospital of Jiangnan University
-
Contact:
- Chunjing Yu
- Phone Number: 15312238622
- Email: ycj_wxd1978@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patients with pathologically confirmed metastatic renal clear cell carcinoma;
- Age range from 18 to 75 years old (including 18 and 75 years old);
- ECOG score of 0 or 1;
- Expected life > 6 months;
- GFR> 60 ml/min;
- Women of childbearing age need to have a negative pregnancy test, and the subjects(including male subjects)agree to take effective contraceptive measures during the study period and for at least three months after the drug administration;
- The subjects are able to maintain good communication with the researchers;understand and follow the requirements of this study and sign an informed consent form before the start of relevant research operations.
Exclusion Criteria:
- Pregnant or lactating women, or women who plan to conceive during the study period or within three months after drug administration;
- Known or suspected to be allergic to the investigational drug or any of its components,acetazolamide or other sulfonamides:
- Accepting other investigational drugs upon enrollment, or within 5 biological half-lives of the drug at enrollment, or within 30 days after its last administration, whichever is longer;
- Those who have used any radioactive therapy medication within 90 days before investigational drug administration, or have received any radioactive diagnostic medication within 3 days before investigational drug administration;
- On VEGF TKI treatment less than 7 days before 68Ga-NYM005 PET/CT, such as sunitinib,sorafenib, cabozantinib, pazopanib, or lenvatinib, a washout of one week before 68Ga-NYM005 PET/CT is required;
- Planned (for the period between injection of 68Ga-NYM005 and imaging) antineoplastic therapies;
- Plan to arrange surgery and other invasive interventions within 2 days after the injection of the investigational drug;
- Ongoing toxicity >grade l from previous standard or investigational therapies;
- Patients with active infections during screening;
- Those who have no guarantee of being able to lie down quietly in the examination cabin during a PET examination, or those who suffer from claustrophobia and cannot cooperate in a PET examination:
- Other situations where the researchers believe that the subject is not suitable for inclusion in this study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 68Ga-NYM005 injection
|
he radiation dose is about 2-7 mCi for a single patient.Using a syringe to withdraw 68Ga-NYM005 injection, the dose will be administered via an intravenous injection and the injection time will be about 45-60 seconds.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of Adverse Events
Time Frame: 5 days
|
5 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
May 1, 2024
Primary Completion (Estimated)
December 1, 2024
Study Completion (Estimated)
December 1, 2024
Study Registration Dates
First Submitted
April 24, 2024
First Submitted That Met QC Criteria
April 24, 2024
First Posted (Actual)
April 29, 2024
Study Record Updates
Last Update Posted (Actual)
April 29, 2024
Last Update Submitted That Met QC Criteria
April 24, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Kidney Diseases
- Urologic Diseases
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Kidney Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Carcinoma, Renal Cell
- Carcinoma
Other Study ID Numbers
- CP-2023-02
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Clear Cell Renal Cell Carcinoma Metastatic
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | Unresectable Renal Cell... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingMetastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | Advanced Sarcomatoid Renal...United States
-
Celldex TherapeuticsTerminatedKidney Neoplasms | Metastatic Renal Cell Carcinoma | Ovarian Clear Cell Carcinoma | Papillary Renal Cell Carcinoma | Renal Cell Carcinoma (RCC) | Clear-cell Renal Cell CarcinomaUnited States
-
Association Pour La Recherche des Thérapeutiques...CompletedClear-cell Metastatic Renal Cell Carcinoma | Clear-cell Renal CarcinomaFrance
-
Millennium Pharmaceuticals, Inc.CompletedClear-cell Metastatic Renal Cell CarcinomaSpain, Czechia, United States, Canada, Italy, United Kingdom, France, Poland
-
Rennes University HospitalCompletedMetastatic Clear Cell Renal Cell CarcinomaFrance
-
Radboud University Medical CenterCompletedMetastatic Clear Cell Renal Cell CarcinomaNetherlands
-
Celldex TherapeuticsTerminatedNeoplasms | Neoplasms by Histologic Type | Kidney Neoplasms | Carcinoma, Renal Cell | Urologic Neoplasms | Urogenital Neoplasms | Kidney Diseases | Urologic Diseases | Clear-cell Metastatic Renal Cell CarcinomaUnited States
-
Australian and New Zealand Urogenital and Prostate...Merck Sharp & Dohme LLC; AmgenActive, not recruitingRenal Cell Carcinoma, Clear Cell | Metastatic Kidney CancerAustralia
-
University of Texas Southwestern Medical CenterTerminatedMetastatic Clear Cell Renal Cell CarcinomaUnited States
Clinical Trials on 68Ga-NYM005 injection
-
Peking Union Medical College HospitalRecruitingClear Cell Renal Cell CarcinomaChina
-
Peking Union Medical College HospitalRecruiting
-
Peking Union Medical College HospitalRecruitingClear Cell Renal Cell CarcinomaChina
-
Peking Union Medical College HospitalRecruitingMetastatic Clear Cell Renal Cell CarcinomaChina
-
Peking Union Medical College HospitalRecruiting
-
Hexin (Suzhou) Pharmaceutical Technology Co., LtdWuhan Union Hospital, ChinaCompleted
-
Peking Union Medical College HospitalRecruiting
-
Norroy Bioscience Co., LTDRecruiting
-
Peking Union Medical College HospitalRecruitingBreast Cancer | Prostate Cancer | Brain Tumor | PET/CT ImagingChina